105 related articles for article (PubMed ID: 22098185)
1. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
[TBL] [Abstract][Full Text] [Related]
2. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.
Dresch KF; Mattos AA; Tovo CV; Onofrio FQ; Casagrande L; Feltrin AA; Barros IC; Almeida PR
Rev Inst Med Trop Sao Paulo; 2016; 58():37. PubMed ID: 27253739
[TBL] [Abstract][Full Text] [Related]
3. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
Nudo CG; Wong P; Hilzenrat N; Deschênes M
Can J Gastroenterol; 2006 Sep; 20(9):589-92. PubMed ID: 17001400
[TBL] [Abstract][Full Text] [Related]
4. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.
Tsai SM; Kao JT; Tsai YF
BMC Health Serv Res; 2016 Jul; 16():247. PubMed ID: 27402141
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.
Rasimas J; Katsounas A; Raza H; Murphy AA; Yang J; Lempicki RA; Osinusi A; Masur H; Polis M; Kottilil S; Rosenstein D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):273-81. PubMed ID: 22728749
[TBL] [Abstract][Full Text] [Related]
6. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.
Cacopardo B; Benanti F; Pinzone MR; Nunnari G
BMC Res Notes; 2013 Oct; 6():437. PubMed ID: 24171974
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS; Aspinall E; Liew D; Thompson AJ; Hellard ME
Br J Clin Pharmacol; 2013 Apr; 75(4):931-43. PubMed ID: 22882367
[TBL] [Abstract][Full Text] [Related]
8. Chronic Hepatitis C: Treatment, Complications, and Long-term Outcomes in a Population of Latino Veterans.
Santiago-Rolón A; Purcell D; Grigg N; Toro DH
P R Health Sci J; 2016 Mar; 35(1):30-4. PubMed ID: 26932282
[TBL] [Abstract][Full Text] [Related]
9. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective.
Tran HA; Jones TL; Ianna EA; Foy A; Reeves GE
Endocr Pract; 2013; 19(2):292-300. PubMed ID: 23186968
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Combination Antiviral Therapy in the Treatment of Hepatitis C on the Occurrence of Depressive Disorder in Patients Treated for Hepatitis C in the Republic of Srpska.
Banjac V; Zivlak-Radulovic N; Miskovic M
Med Arch; 2016 Apr; 70(2):127-30. PubMed ID: 27147788
[TBL] [Abstract][Full Text] [Related]
11. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.
Zaily DG; Marlen CF; Santiago DC; Gillian MD; Carmen VS; Zurina CE; Enrique R AS; Liz AL; Lisset GF; Sacha LDV; Elena FB
Curr Ther Res Clin Exp; 2017; 85():20-28. PubMed ID: 29158855
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.
Jakacki RI; Dombi E; Potter DM; Goldman S; Allen JC; Pollack IF; Widemann BC
Neurology; 2011 Jan; 76(3):265-72. PubMed ID: 21242495
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
Raison CL; Demetrashvili M; Capuron L; Miller AH
CNS Drugs; 2005; 19(2):105-23. PubMed ID: 15697325
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of pegylated interferon alpha-2b for patients with myeloproliferative neoplasm].
Teng GS; Zhang YH; Wang Y; Du CX; Li YQ; Hu NB; Xiang GP; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3645-3651. PubMed ID: 38018063
[No Abstract] [Full Text] [Related]
15. Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries.
Aziz S
J Clin Transl Hepatol; 2014 Dec; 2(4):247-52. PubMed ID: 26356647
[TBL] [Abstract][Full Text] [Related]
16. Forms and Methods for Interferon's Encapsulation.
Ramos TI; Villacis-Aguirre CA; Santiago Vispo N; Santiago Padilla L; Pedroso Santana S; Parra NC; Alonso JRT
Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683824
[TBL] [Abstract][Full Text] [Related]
17. Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
Ogawa E; Nakamuta M; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Ooho A; Azuma K; Takahashi K; Satoh T; Koyanagi T; Yamashita N; Ichiki Y; Yamashita N; Kuniyoshi M; Yanagita K; Amagase H; Morita C; Sugimoto R; Kato M; Shimoda S; Nomura H; Hayashi J;
J Gastroenterol Hepatol; 2022 Jan; 37(1):190-199. PubMed ID: 34374128
[TBL] [Abstract][Full Text] [Related]
18. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Kawano A; Shigematsu H; Miki K; Ichiki Y; Morita C; Yanagita K; Takahashi K; Dohmen K; Nomura H; Ishibashi H; Shimoda S
Intern Med; 2018 Jun; 57(11):1533-1542. PubMed ID: 29321441
[TBL] [Abstract][Full Text] [Related]
19. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.
Dyall J; Gross R; Kindrachuk J; Johnson RF; Olinger GG; Hensley LE; Frieman MB; Jahrling PB
Drugs; 2017 Dec; 77(18):1935-1966. PubMed ID: 29143192
[TBL] [Abstract][Full Text] [Related]
20. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
